LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gut Microbiota Differ in Men With Prostate Cancer

By LabMedica International staff writers
Posted on 06 Jul 2022
Print article
Image: Petri dish culture plate with bacterial colonial growth of Prevotella spp., The men with cancer had increased levels Prevotella-9 (Photo courtesy of Dr. V.R. Dowell)
Image: Petri dish culture plate with bacterial colonial growth of Prevotella spp., The men with cancer had increased levels Prevotella-9 (Photo courtesy of Dr. V.R. Dowell)

Gut microbiota are the collection of microbes in the gastrointestinal tract and they affect processes and mechanisms in the body. The state of gut microbiota has been linked to many conditions, even in organs that are far from the intestines, but their role in prostate cancer is not understood.

Prostate cancer is the most common male cancer globally, but varying rates in different parts of the world are little understood. It is common in most Western countries and less common elsewhere. Though it is known to be hereditary, there is evidence that men who emigrated from low to high incidence areas have increased risk of prostate cancer in their lifetimes, and their offspring have the risk of the high incidence region.

Clinical Urologists at theUniver sity of Turku (Turku, Finland) and their colleagues used samples collected from patients on a prospective multi-center clinical study. They sequenced the gut microbiota of 181 men who were suspected to have prostate cancer and undergoing prostate cancer diagnostics. The microbiota samples were collected at the time of their prostate biopsies after MRI scans.

The investigators reported that 60% of the men were diagnosed with prostate cancer, and their gut microbiota profiles were significantly different to those who had benign biopsies. The men with cancer had increased levels of Prevotella 9, members of the family Erysipelotrichaceae, and Escherichia-Shigella, a pathogen that causes diarrhea. They also had lower levels of Jonquetella, Moryella, Anaeroglobus, Corynebacterium and Clostridium sp., CAG-352 than men who had no cancer.

Peter Bostrom, MD, PhD, a Professor of Urology and lead author of the study, said, “There are significant variations in prostate cancer rates around the world, which could be due to genetic factors or differences in healthcare policies, but also variance in lifestyle and diet. The difference in gut microbiota between men with and without prostate cancer could underpin some of these variations. More studies are needed to look at the potential for using gut microbiota for both diagnostic and preventive strategies.” The study was presented at the European Association of Urology annual congress held July 1-4, 2022, in Amsterdam, the Netherlands.

Related Links:
University of Turku

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.